Video
Dr. Dorff on Current Agents for Patients With mCRPC
Author(s):
Tanya B. Dorff, MD, associate professor of clinical medicine, University of Southern California, discusses current agents available for patients with metastatic castration-resistant prostate cancer (mCRPC).
Tanya B. Dorff, MD, associate professor of clinical medicine, University of Southern California, discusses current agents available for patients with metastatic castration-resistant prostate cancer (mCRPC).
There are several agents available to treat patients with mCRPC, such as abiraterone acetate (Zytiga), enzalutamide (Xtandi), and docetaxel. However, patients treated with upfront intensification complicates the treatment process, says Dorff.
Novel agents, such as immunotherapy and PARP inhibitors, are being compared to these older agents in clinical trials, explains Dorff.
